As part of our series focussing on available medicines in Australia, we have added a product review of the use of ponatinib hydrochloride for chronic myeloid leukaemia.
This publication focuses on the use of a novel, response-based, dose reduction strategy for ponatinib that reduces the incidence of arterial occlusive events while maintaining efficacy in patients with chronic-phase chronic myeloid leukaemia. It also provides commentary from Associate Professor David Ross, Consultant Haematologist in SA Pathology with clinical appointments at the Royal Adelaide Hospital and Flinders Medical Centre in Adelaide.
Please login below to download this issue (PDF)